Gore Range Capital

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that will improve clinical practice and help reduce patient mortality.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Validic, Inc. is a technology company that provides a cloud-based platform for collecting and managing mobile health data from various Internet-enabled health applications and devices. Founded in 2010 and based in Durham, North Carolina, Validic connects healthcare providers with patient-recorded data through its solutions, including Validic Solution, Validic Connect, and Validic Mobile. The platform integrates data from over 400 clinical and consumer devices, enabling wellness companies, healthcare providers, pharmaceuticals, and health plans to access and utilize actionable health information. By streamlining the collection and visualization of personal health data, Validic aims to enhance the quality of care and improve health outcomes for individuals.

Eirion Therapeutics is a clinical-stage biopharmaceutical company that is developing next-generation prescription products for aesthetic dermatology. The company currently has a rich pipeline of products focusing on treatments for wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. In the future, Eirion plans to also pursue additional indications that address other major unmet clinical needs for physicians and their patients.

Dorsata enables healthcare providers to make better decisions that are informed by data and best practices. The company provides teams of clinicians tools to build, share, and then use defined workflows, called care pathways, for efficient decision-making, documentation, and order entry. Leveraging these clinician-developed care pathways, Dorsata is committed to transforming healthcare from a cost-reduction and quality improvement standpoint. Dorsata was founded in 2011 and is headquartered in Washington, District of Columbia, United States.

CoreMedica Laboratories Inc. specializes in the development of blood serum separation and transportation containers designed for various applications, including corporate wellness, epidemiological research, pharmaceutical studies, clinical trials monitoring, and insurance underwriting. Founded in 2010 and headquartered in Lee's Summit, Missouri, the company offers micro and dried blood collection and analysis tools and services. All testing of samples is conducted in its laboratory, which is accredited by the College of American Pathologists (CAP) and certified by the Clinical Laboratory Improvement Amendments (CLIA).

Claret Medical, Inc. is a medical device company specializing in cerebral vascular protection systems designed to mitigate the risk of stroke during transcatheter aortic valve implantation and other endovascular procedures. Established in 2009 and headquartered in Santa Rosa, California, the company's flagship products include the Claret Medical Sentinel Cerebral Protection System and the Claret Medical Montage, both of which serve as embolic protection devices. These systems utilize small catheters, which are inserted through an artery in the patient's arm and positioned near the heart, to capture and remove embolic debris that may be dislodged during procedures. By preventing this debris from entering the cerebral vascular system, Claret Medical's products aim to enhance patient safety during high-risk cardiovascular interventions. The company operates as a subsidiary of Boston Scientific Corporation.

Medikly, Inc. is a digital marketing platform that assists healthcare marketers in effectively reaching and engaging physicians. Founded in 2009 and based in Jersey City, New Jersey, the company offers a comprehensive solution that allows pharmaceutical brands to form deeper connections with physicians by leveraging actionable insights derived from physician intelligence. Medikly's platform serves as an operating system for healthcare marketers, enabling them to continuously collect, analyze, and manage data from various digital channels. In addition to its core platform, Medikly provides services such as campaign execution, modification, and measurement, along with consulting, support, and training, all aimed at enhancing the efficiency of marketing efforts in the healthcare sector.

Founded by the former Dean of the Engineering school of the University of Wisconsin Milwaukee, NovaScan has developed and is committed to commercializing its breakthrough technology for cancer detection – solutions that require no capital equipment, are not constrained by size, provide instantaneous results, and unmatched accuracy.

Founded by the former Dean of the Engineering school of the University of Wisconsin Milwaukee, NovaScan has developed and is committed to commercializing its breakthrough technology for cancer detection – solutions that require no capital equipment, are not constrained by size, provide instantaneous results, and unmatched accuracy.

Dorsata enables healthcare providers to make better decisions that are informed by data and best practices. The company provides teams of clinicians tools to build, share, and then use defined workflows, called care pathways, for efficient decision-making, documentation, and order entry. Leveraging these clinician-developed care pathways, Dorsata is committed to transforming healthcare from a cost-reduction and quality improvement standpoint. Dorsata was founded in 2011 and is headquartered in Washington, District of Columbia, United States.

Castle Biosciences, Inc. is a commercial-stage biotechnology company focused on developing and commercializing diagnostic and prognostic tests for dermatological cancers. The company's lead product, DecisionDx-Melanoma, is a multi-gene expression profile test designed to identify stage I and II melanoma patients at high risk of metastasis by analyzing biological information from 31 genes in tumor tissue. In addition, Castle Biosciences offers the DecisionDx-UM test, which predicts metastasis risk in uveal melanoma patients, and is developing two late-stage products targeting cutaneous squamous cell carcinoma and suspicious pigmented lesions. The company's tests provide personalized, clinically actionable genomic information to assist physicians and patients in making informed treatment decisions. Founded in 2007 and headquartered in Friendswood, Texas, Castle Biosciences aims to significantly impact cancer diagnosis and management through its innovative diagnostic solutions.